Walvax Biotechnology Co., Ltd. (SHE:300142)
China
· Delayed Price · Currency is CNY 12.92
+0.07 (0.54%)
Apr 29, 2026, 1:55 PM CST
Walvax Biotechnology Revenue
Walvax Biotechnology had revenue of 443.85M CNY in the quarter ending March 31, 2026, a decrease of -3.98%. This brings the company's revenue in the last twelve months to 2.40B, down -10.59% year-over-year. In the year 2025, Walvax Biotechnology had annual revenue of 2.42B, down -14.29%.
Revenue (ttm)
2.40B
Revenue Growth
-10.59%
P/S Ratio
8.56
Revenue / Employee
1.21M
Employees
1,981
Market Cap
20.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.42B | -403.21M | -14.29% |
| Dec 31, 2024 | 2.82B | -1.29B | -31.41% |
| Dec 31, 2023 | 4.11B | -972.67M | -19.12% |
| Jan 1, 2023 | 5.09B | 1.62B | 46.89% |
| Jan 1, 2022 | 3.46B | 523.81M | 17.82% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Joincare Pharmaceutical Group Industry | 14.85B |
| Tonghua Dongbao Pharmaceutical | 2.95B |
| China Resources Double-Crane Pharmaceutical | 10.73B |
| Hybio Pharmaceutical | 898.10M |
| Fujian Cosunter Pharmaceutical | 430.98M |
| Wanbangde Pharmaceutical Holding Group | 1.14B |
| China Resources Jiangzhong Pharmaceutical Co.,Ltd | 4.07B |
| Betta Pharmaceuticals | 3.73B |